Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Gufic Biosciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1985 on BSE, Oct 2004 on NSE
Last close ₹420.45up ₹13.10 (3.22%)BSE ₹421.15
Share price at the NSE close on 27 Oct 2026. Previous close ₹407.35.
27 Oct: open ₹407.45, high ₹422.80, low ₹405.35
52-week range of traded prices to 27 Oct 2026
₹268.00Low, 9 Mar 2026₹467.80High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,216 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.40
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 64,57361.3% delivered
Gufic Biosciences has 608 announcements on record, routine notices left out; 2 in the 30 days to 28 Oct 2026, the latest on 23 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Gufic Biosciences quarterly results
Aug14Fri
The board met on 14 Aug 2026 to consider financial results
Notice filed 10 Aug 2026
Gufic Biosciences annual reports, presentations and earnings calls
The company's own documents, latest first.Gufic Biosciences financials, year by year
Annual reports16
- Annual report, year to Mar 202612 Aug 2026
- Annual report, year to Mar 20255 Sep 2025
- Annual report, year to Mar 202431 Aug 2024
- Annual report, year to Mar 20236 Sep 2023, a zip file
- Annual report, year to Mar 202210 Aug 2022, a zip file
11 earlier reports
- Annual report, year to Mar 202020 Oct 2020, a zip file
- Annual report, year to Mar 20197 Sep 2019, a zip file
- Annual report, year to Mar 201829 Sep 2018, a zip file
- Annual report, year to Mar 20179 Sep 2017, a zip file
- Annual report, year to Mar 201615 Oct 2016, a zip file
- Annual report, year to Mar 201521 Oct 2015, a zip file
- Annual report, year to Mar 201424 Sep 2014, a zip file
- Annual report, year to Mar 201325 Sep 2013, a zip file
- Annual report, year to Mar 201218 Sep 2012, a zip file
- Annual report, year to Mar 201115 Jun 2012, a zip file
- Annual report, year to Mar 201015 Jun 2012, a zip file
Investor presentations16
- Investor Presentation for the Quarter ended June 30, 2026 is attached herewith14 Aug 2026
- Investor Presentation is attached herewith29 May 2026
- Investor Presentation13 Feb 2026
- Investor Presentation14 Nov 2025
- Investor Presentation13 Aug 2025
11 earlier presentations
- Investor Presentation30 May 2025
- Investor Presentation14 Feb 2025
- Investor Presentation14 Nov 2024
- Investor Presentation14 Aug 2024
- Presentation29 May 2024
- Investor Presentation14 Feb 2024
- Investor Presentation17 Nov 2023
- Investor Presentation29 May 2023
- Investor Presentation11 Nov 2022
- Investor Presentation11 Aug 2022
- Investor Presentation11 Nov 2020
Earnings calls39
- Transcript21 Aug 2026
- Link of Recording17 Aug 2026
- Written Transcript of Earnings Conference Call held on June 01, 2026 at 04:30 PM is attached herewith.5 Jun 2026
- Link of Recording1 Jun 2026
- Transcript20 Feb 2026
34 earlier call documents
- Link of Recording16 Feb 2026
- Transcript21 Nov 2025
- Link of Recording17 Nov 2025
- Written Transcript of Earnings Conference Call20 Aug 2025
- Link of Recording14 Aug 2025
- Transcript6 Jun 2025
- Link of Recording2 Jun 2025
- Transcript21 Feb 2025
- Link of Recording17 Feb 2025
- Transcript22 Nov 2024
- Link of Recording18 Nov 2024
- Transcript20 Aug 2024
- Link of Recording14 Aug 2024
- Transcript5 Jun 2024
- Link of Recording30 May 2024
- Transcript21 Feb 2024
- Link of Recording16 Feb 2024
- Transcript23 Nov 2023
- Link of Recording17 Nov 2023
- Transcript18 Aug 2023
- Link of Recording14 Aug 2023
- Transcript2 Jun 2023
- Link of Recording30 May 2023
- Transcript24 Feb 2023
- Written Transcript of Analysts/Institutional Investor Meet/Con. Call18 Nov 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call14 Nov 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call18 Aug 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call12 Aug 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call27 May 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call23 May 2022
- Transcript14 Feb 2022
- Link of Recording10 Feb 2022
- Transcript16 Nov 2021
- Link of Recording10 Nov 2021
Gufic Biosciences merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings12
- Amalgamation/Merger27 May 2021
- Amalgamation/Merger17 Mar 2021
- Amalgamation/Merger4 Jan 2021
- Amalgamation/Merger3 Jul 2020
- Amalgamation/Merger16 Apr 2020
7 earlier filings
- With reference to the captioned subject, we hereby inform that the Board of Directors of the Company at its Meeting held today i.e. March 25, 2019, inter alia approved the Scheme of Amalgamation of Gufic Lifesciences Private Limited with the Company and their respective shareholders and creditors ( Scheme). The above Scheme is in substitution of the Scheme intimated vide letter dated September 20, 2018 to the Stock Exchanges and the revision is due to change in shareholding pattern of Gufic Lifesciences Private Limited.The details as required under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed herewith as Annexure A.25 Mar 2019
- Intimation of trading approval obtained from Stock Exchanges for 4,80,000 Equity Shares of Re. 1/- each bearing distinctive nos from 77350001 to 77830000 (both inclusive) issued pursuant to the Scheme of Merger by Absorption of Gufic Stridden Bio-Pharma Private Limited ( Transferor Company) with Gufic Biosciences Limited ( Transferee Company) and its respective shareholders.3 Nov 2018
- Documents post approval of Scheme by the National Company Law Tribunal (NCLT), Mumbai Bench.5 Oct 2018
- Board of Directors of the Company at its Meeting held on September 20, 2018, inter alia has approved the Scheme of Amalgamation of Gufic Lifesciences Private Limited with the Company and their respective shareholders and creditors.21 Sep 2018
- National Company Law Tribunal, Mumbai bench (NCLT) order sanctioning the Scheme of Merger by Absorption of Gufic Stridden Bio-Pharma Private Limited ("Transferor Company") with Gufic Biosciences Limited ("Transferee Company") and their respective shareholders.12 Sep 2018
- Order by National Company Law Tribunal, Mumbai bench sanctioning the Scheme of Merger by Absorption of Gufic Stridden Bio-Pharma Private Limited with Gufic Biosciences Limited and their respective shareholders7 Sep 2018
- Approval of Amalgamation of M/s. Gufic Stridden Bio-Pharma Private Limited with the Company subject to necessary approvals.25 Nov 2016, a zip file
Gufic Biosciences share news and announcements
Newest first. Page 1 of 13.
Oct 2026
Sep 2026
28 Sep · General Updates
8 Sep · Rating
2 Sep · General Updates
Aug 2026
14 Aug · General Updates
14 Aug · Business
Jul 2026
31 Jul · Board meeting
Jun 2026
May 2026
29 May · Management
29 May · Business
29 May · Board meeting
25 May · Analysts
Apr 2026
29 Apr · General Updates
Mar 2026
Feb 2026
13 Feb · Board meeting
13 Feb · Results
10 Feb · Analysts
4 Feb · Analysts
Jan 2026
Dec 2025
10 Dec · General Updates
Nov 2025
17 Nov · Analysts
11 Nov · Analysts
10 Nov · Rating
Sep 2025
29 Sep · Meeting
18 Sep · Analysts
Aug 2025
13 Aug · Management
13 Aug · Management
13 Aug · Results
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 9 Sep 2026Credit ratingdown 2.60%−2.0 pts vs Nifty 500market median 0.0% · five sessions −4.6% (−2.2 pts vs Nifty 500) · volume 0.5× usual · delivery +1.8 pts against usual · The announcement
- 17 Aug 2026Resultsdown 0.95%−0.8 pts vs Nifty 500market median −0.7% · five sessions +2.2% (+2.5 pts vs Nifty 500) · volume 3.5× usual · delivery −18.6 pts against usual · The announcement
- 1 Jun 2026Resultsup 3.85%+4.8 pts vs Nifty 500market median −0.7% · five sessions +10.8% (+11.7 pts vs Nifty 500) · volume 4.4× usual · delivery −4.8 pts against usual · The announcement
- 1 Jun 2026Dividendup 3.85%+4.8 pts vs Nifty 500market median 0.0% · five sessions +10.8% (+11.7 pts vs Nifty 500) · volume 4.4× usual · delivery −4.8 pts against usual · The announcement
- 16 Feb 2026Resultsdown 5.33%−6.0 pts vs Nifty 500market median −0.7% · five sessions −6.8% (−7.1 pts vs Nifty 500) · volume 3.2× usual · delivery +9.2 pts against usual · The announcement
- 17 Nov 2025Resultsdown 1.54%−2.0 pts vs Nifty 500market median −0.7% · five sessions +10.8% (+11.0 pts vs Nifty 500) · volume 0.7× usual · delivery +2.5 pts against usual · The announcement
- 11 Nov 2025Credit ratingup 0.30%−0.1 pts vs Nifty 500market median 0.0% · five sessions −1.4% (−2.9 pts vs Nifty 500) · volume 0.9× usual · delivery −3.8 pts against usual · The announcement
- 14 Aug 2025Resultsdown 0.06%0.0 pts vs Nifty 500market median −0.7% · five sessions +3.6% (+1.7 pts vs Nifty 500) · volume 1.7× usual · delivery −24.1 pts against usual · The announcement
- 2 Jun 2025Resultsdown 6.37%−6.5 pts vs Nifty 500market median −0.7% · five sessions −5.9% (−7.4 pts vs Nifty 500) · volume 4.6× usual · delivery +5.4 pts against usual · The announcement
- 5 May 2025Board or managers changedup 0.46%−0.4 pts vs Nifty 500market median 0.0% · five sessions −1.6% (−0.1 pts vs Nifty 500) · volume 0.5× usual · delivery +3.6 pts against usual · The announcement
20 earlier announcements
- 17 Feb 2025Resultsup 0.41%+0.3 pts vs Nifty 500market median −0.7% · five sessions −4.2% (−4.5 pts vs Nifty 500) · volume 1.6× usual · delivery −10.6 pts against usual · The announcement
- 14 Aug 2024Resultsdown 2.58%−2.4 pts vs Nifty 500market median −0.7% · five sessions +2.3% (−0.6 pts vs Nifty 500) · volume 0.9× usual · delivery −12.1 pts against usual · The announcement
- 14 Aug 2024Board or managers changeddown 2.58%−2.4 pts vs Nifty 500market median 0.0% · five sessions +2.3% (−0.6 pts vs Nifty 500) · volume 0.9× usual · delivery −12.1 pts against usual · The announcement
- 2 Aug 2024Credit ratingdown 0.71%+0.3 pts vs Nifty 500market median 0.0% · five sessions +2.7% (+6.1 pts vs Nifty 500) · volume 0.5× usual · delivery +2.0 pts against usual · The announcement
- 28 Jun 2024Board or managers changeddown 0.46%−0.6 pts vs Nifty 500market median 0.0% · five sessions +5.9% (+4.2 pts vs Nifty 500) · volume 0.2× usual · delivery −2.8 pts against usual · The announcement
- 30 May 2024Dividenddown 2.49%−1.5 pts vs Nifty 500market median 0.0% · five sessions −2.6% (−1.7 pts vs Nifty 500) · volume 1.4× usual · delivery +3.9 pts against usual · The announcement
- 15 Feb 2024Resultsdown 2.98%−3.6 pts vs Nifty 500market median −0.7% · five sessions −4.1% (−5.1 pts vs Nifty 500) · volume 0.8× usual · delivery +7.7 pts against usual · The announcement
- 10 Nov 2023Resultsdown 1.60%−1.8 pts vs Nifty 500market median −0.7% · five sessions +13.5% (+11.3 pts vs Nifty 500) · volume 1.1× usual · delivery −6.1 pts against usual · The announcement
- 30 May 2023Dividenddown 4.69%−4.9 pts vs Nifty 500market median 0.0% · five sessions −6.3% (−6.8 pts vs Nifty 500) · volume 3.0× usual · delivery +8.5 pts against usual · The announcement
- 9 May 2023Credit ratingup 0.48%+0.5 pts vs Nifty 500market median 0.0% · five sessions +1.0% (+0.2 pts vs Nifty 500) · volume 1.0× usual · delivery +6.3 pts against usual · The announcement
- 14 Nov 2022Resultsdown 4.21%−4.2 pts vs Nifty 500market median −0.7% · five sessions −8.8% (−8.2 pts vs Nifty 500) · volume 2.2× usual · delivery +7.0 pts against usual · The announcement
- 13 Oct 2022Credit ratingdown 1.68%−1.0 pts vs Nifty 500market median 0.0% · five sessions −5.2% (−6.8 pts vs Nifty 500) · volume 0.4× usual · delivery +5.5 pts against usual · The announcement
- 27 Jun 2022Credit ratingup 4.72%+3.8 pts vs Nifty 500market median 0.0% · five sessions −2.7% (−3.3 pts vs Nifty 500) · volume 1.5× usual · delivery +18.0 pts against usual · The announcement
- 23 May 2022Resultsdown 6.15%−5.7 pts vs Nifty 500market median −0.7% · five sessions −10.5% (−10.3 pts vs Nifty 500) · volume 0.9× usual · delivery +9.2 pts against usual · The announcement
- 23 May 2022Dividenddown 6.15%−5.7 pts vs Nifty 500market median 0.0% · five sessions −10.5% (−10.3 pts vs Nifty 500) · volume 0.9× usual · delivery +9.2 pts against usual · The announcement
- 8 Apr 2022Credit ratingup 0.28%−0.7 pts vs Nifty 500market median 0.0% · five sessions +1.7% (+3.5 pts vs Nifty 500) · volume 0.4× usual · delivery +4.4 pts against usual · The announcement
- 27 Oct 2021Credit ratingup 8.27%+8.4 pts vs Nifty 500market median 0.0% · five sessions +5.1% (+6.3 pts vs Nifty 500) · volume 3.6× usual · delivery −11.5 pts against usual · The announcement
- 12 Aug 2021Resultsup 13.38%+12.7 pts vs Nifty 500market median −0.7% · five sessions +7.7% (+6.2 pts vs Nifty 500) · volume 16.5× usual · delivery −22.0 pts against usual · The announcement
- 7 Jun 2021Dividenddown 2.28%−2.9 pts vs Nifty 500market median 0.0% · five sessions −2.0% (−3.3 pts vs Nifty 500) · volume 0.3× usual · delivery +10.7 pts against usual · The announcement
- 8 Mar 2021Credit ratingdown 0.61%−0.8 pts vs Nifty 500market median 0.0% · five sessions −4.1% (−3.9 pts vs Nifty 500) · volume 0.3× usual · delivery +9.5 pts against usual · The announcement
Gufic Biosciences results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Revenue from operations | Quarter to Jun 2018 | Standalone | 78.49 | 78.78 | +0.4% | 18 Aug 2018 | 20 Nov 2018 |
| Other income | Quarter to Jun 2018 | Standalone | 0.22 | 0.33 | +45.8% | 18 Aug 2018 | 20 Nov 2018 |
| Total income | Quarter to Jun 2018 | Standalone | 78.72 | 79.11 | +0.5% | 18 Aug 2018 | 20 Nov 2018 |
| Materials used | Quarter to Jun 2018 | Standalone | 32.82 | 33.32 | +1.5% | 18 Aug 2018 | 20 Nov 2018 |
| Employee costs | Quarter to Jun 2018 | Standalone | 14.77 | 14.81 | +0.2% | 18 Aug 2018 | 20 Nov 2018 |
| Finance costs | Quarter to Jun 2018 | Standalone | 1.93 | 1.95 | +0.8% | 18 Aug 2018 | 20 Nov 2018 |
| Depreciation and amortisation | Quarter to Jun 2018 | Standalone | 0.93 | 0.95 | +2.0% | 18 Aug 2018 | 20 Nov 2018 |
| Other expenses | Quarter to Jun 2018 | Standalone | 15.73 | 16.06 | +2.0% | 18 Aug 2018 | 20 Nov 2018 |
| Total expenses | Quarter to Jun 2018 | Standalone | 72.19 | 72.83 | +0.9% | 18 Aug 2018 | 20 Nov 2018 |
| Profit before tax | Quarter to Jun 2018 | Standalone | 6.52 | 6.28 | −3.7% | 18 Aug 2018 | 20 Nov 2018 |